The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with Alzheimer's dementia and performing an attention test on baseline, week 4 and 12.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Alzheimer's disease according to the criteria of DSM-IV, NINCDS-ADRDA

• K-MMSE (Korean - Mini Mental State Exam) is 10 to 24

• Reliable Guardian available to the patients

• Patient or guardian provided written informed consent before entering into the clinical trial

Exclusion Criteria:

• Acetylcholine esterase inhibitors used to treat dementia taken within 30 days of the beginning in this clinical trial

• Neurodegenerative diseases (eg Parkinson's disease, Pick's disease, Huntington's disease, Down syndrome)

• Dementia related to head trauma and dementia related to brain damage due to cerebral hypoxia (hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due to shock)

• brain tumor, nerve syphilis, meningitis, encephalitis

• epilepsy